688506 Sichuan Biokin Pharmaceutical
- 153.39
- +8.95+6.20%
Sichuan Biokin Pharmaceutical News
Baili Tianheng (688506.SH): 2023 net profit - 780 million yuan
Gelonghui, April 26丨Baili Tianheng (688506.SH) released its 2023 annual report. During the reporting period, the company achieved operating revenue of 562 million yuan, a decrease of 20.11% over the same period last year. Net profit attributable to listed companies - $780 million, a decrease of 176.40% compared with the same period last year. The main reason was that phase III clinical trials continued to be invested in pre-clinical research and clinical trial research during the reporting period. As R&D progress continued to advance, R&D investment increased, leading to a continuous increase in the company's R&D expenses.
Sichuan Biokin Pharmaceutical Gets Approval to Trial Lung Cancer Drug
Sichuan Biokin Pharmaceutical (SHA:688506) will conduct clinical trials on BL-B01D1 for injection after receiving approval from China's National Medical Products Administration, according to the compa
Express News | Baili Tianheng announced that the self-developed combination drug “BL-B01D1PD-1 monoclonal antibody ± chemotherapy” related to BL-B01D1 (EGFR×HER3-ADC) for injecting innovative biopharmaceuticals for treatment of locally advanced or metastatic non-small c
Express News | Baili Tianheng: “BL-B01D1 PD-1 monoclonal antibody ± chemotherapy” for locally advanced or metastatic non-small cell lung cancer received approval notice for phase II clinical trials
Chinese Drug Regulator Puts Sichuan Biokin Pharmaceutical's Naxopharynx Cancer Drug in Breakthrough Drugs List
China's National Medical Products Administration included Sichuan Biokin Pharmaceutical's (SHA:688506) BL-B01D1 for injection in the list of breakthrough therapy drugs, according to the company's disc
Baili Tianheng (688506.SH): Injectable BL-B01D1 is used to treat terminal patients with locally advanced or metastatic nasopharyngeal cancer included in the list of breakthrough treatment varieties
Baili Tianheng (688506.SH) announced that the company's self-developed innovative biopharmaceutical injectable BL-B01D1...
Dongwu Securities released a research report on April 11 stating that it gave Bailey Tianheng (688506.SH) a purchase rating. The main reasons for the rating include: 1) traditional formulations nurture innovation, paving the way for Baili Tianheng; 2) BL-
Dongwu Securities released a research report on April 11 stating that it gave Bailey Tianheng (688506.SH) a purchase rating. The main reasons for the rating include: 1) traditional formulations nurture innovation, paving the way for Baili Tianheng; 2) BL-B01D1 pioneered a dual-antibody ADC and worked with BMS to create the next blockbuster; 3) ADC and multi-antibody platforms are globally differentiated, and the echelon product portfolio is gradually building a global Biopharm. (Mainichi Keizai Shimbun)
Bailey Tianheng-U (688506): pioneered dual-antibody ADC to write a new chapter in global blockbuster products
Key investment points Traditional formulations nurture innovation and pave the path of globalization: Bailey Tianheng was founded in 1996, and its development has gone through the generic drug stage and the stage of innovation and transformation. In 2010, it laid out innovative drug research and development, and the company already
Express News | Baili Tianheng: BL-B01D1 injection for recurrent or metastatic esophageal squamous cell carcinoma phase III clinical trial completed the first patient enrollment
Express News | Baili Tianheng: “BL-M07D1 PD-1/PD-L1 monoclonal antibody ± chemotherapy” and “BL-M07D1 pertuzumab ± chemotherapy” obtained approval notice for phase II clinical trials
OAP III (HK) Limited, the majority shareholder of Baili Tianheng (688506.SH), reduced its holdings by 1.38% through an inquiry and transfer
Baili Tianheng (688506.SH) issued an announcement. In this inquiry and transfer, the company's shareholder OAP III (...
Baili Tianheng (688506.SH): Preliminary confirmation of the transfer price of this inquiry is 109.25 yuan/share
Baili Tianheng (688506.SH) issued an announcement. According to the inquiry and subscription situation on March 22, 2024, preliminary...
Shareholder of Baili Tianheng (688506.SH) OAP III (HK) Limited plans to transfer 1.50% of the shares through an inquiry
Baili Tianheng (688506.SH) issued an announcement. The company's shareholder OAP III (HK) Lim...
A-share changes | Bailitian Hengpan initially approaches 20CM rise and stop the new drug to obtain approval notice for phase I clinical trials
Glonghui, March 14 | Bailey Tianheng (688506.SH) was close to a 20CM rise and stop at the beginning of the session. It is now reported at 135.4 yuan, with a total market value of 54.3 billion yuan. The company announced yesterday after the market that the injectable BL-M05D1 (ADC) program for treating locally advanced solid tumors has obtained a Phase I clinical trial approval notice. In addition, a down payment of 800 million US dollars from BMS was recently received, and the FIC variety is expected to fulfill its global value.
Express News | Baili Tianheng: BL-M05D1 (ADC) for injectable treatment of locally advanced solid tumors obtained approval notice for phase I clinical trials
Bailey Tianheng-U (688506) Important Review: FIC varieties that have received a down payment of 800 million US dollars from BMS are expected to deliver on global value
Matters: On March 10, 2024, the company announced that it had received a down payment of US$800 million from BMS for the BL-B01D1 development and commercialization license agreement, which is expected to have a positive impact on the 2024 results.
Baili Tianheng (688506.SH): Received US$800 million down payment for BL-B01D1 project
Zhitong Finance App News, Baili Tianheng (688506.SH) announced that on December 11, 2023, SysTimMune, Inc.'s wholly-owned subsidiary SysTimMune, Inc. and Bristol-Myers Squibb (“BMS”, NYSE code: BMY) reached an exclusive license and cooperation agreement for the BL-B01D1 (EGFR×HER3 dual-antibody ADC) project. On February 8, 2024, the cooperation agreement officially came into effect. As of March 7, 2024, the company has received an initial payment of 800 million US dollars from BMS (the actual payment amount is subject to bank charges). The company expects
Express News | 202 science and technology innovation board stocks were reduced by northbound capital, with China Control Technology leading the way in reducing holdings by 2.094,200 shares
Bailey Tianheng (688506): Increased R&D to accelerate the globalization of B01D1
Core view: The company issued a quick report on the 2023 results: achieved total operating income of 5618.707 million yuan in 2023, a year-on-year decrease of 20.11%; realized net profit to mother of 763.90 million
Is Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Analysis
Price Target
No Data
